Panbela Therapeutics, Inc. has announced a delay in the interim data analysis for its ASPIRE trial, now expected in Q1 2025. The delay is attributed to a lower-than-expected event rate, suggesting patients are experiencing improved survival outcomes. The ASPIRE trial is assessing the efficacy and safety of ivospemin (SBP-101) in combination with chemotherapy agents in treating metastatic pancreatic ductal adenocarcinoma (mPDAC). Despite the delay, the company views the extended survival as a positive sign of ivospemin's potential. Panbela also referenced the Napoli 3 trial and the recent approval of Onivyde, noting the modest incremental benefits in median survival for mPDAC treatments. The company remains committed to advancing the ASPIRE trial and plans to share interim results in March 2025. Panbela's pipeline includes clinical trials focusing on various cancers, with ivospemin showing promise in previous studies. The company's stock is quoted on the OTCQB under the symbol 'PBLA'.

Panbela Therapeutics, Inc. has announced a delay in the interim data analysis for its ASPIRE trial, now expected in Q1 2025. The delay is attributed to a lower-than-expected event rate, suggesting patients are experiencing improved survival outcomes. The ASPIRE trial is assessing the efficacy and safety of ivospemin (SBP-101) in combination with chemotherapy agents in treating metastatic pancreatic ductal adenocarcinoma (mPDAC). Despite the delay, the company views the extended survival as a positive sign of ivospemin's potential. Panbela also referenced the Napoli 3 trial and the recent approval of Onivyde, noting the modest incremental benefits in median survival for mPDAC treatments. The company remains committed to advancing the ASPIRE trial and plans to share interim results in March 2025. Panbela's pipeline includes clinical trials focusing on various cancers, with ivospemin showing promise in previous studies. The company's stock is quoted on the OTCQB under the symbol 'PBLA'.